Cartesian Therapeutics, Inc. (RNAC)
RNAC moved a median of +0.11% 30 minutes after news, and 0.00% by the close. How RNAC actually reacts to news — the realized, point-in-time move the market made, measured across 285 labeled events over the last three years with zero look-ahead.
RNAC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 280 |
| 30-min | +0.11% | 51% | 285 |
| 60-min | +0.18% | 51% | 285 |
| to close | 0.00% | 49% | 285 |
| Middle 50% of RNAC reactions | -1.79% to +1.96% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 285 |
Half of all Cartesian Therapeutics, Inc. news events land between -1.79% and +1.96% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RNAC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +1.60% | 70% | +10.71% |
| Coverage initiations | 21 | +0.25% | 67% | +3.62% |
| Rating reiterations | 79 | +0.67% | 61% | +0.04% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how RNAC ranks against every other measured name →
That’s how RNAC usually reacts — get an email when it moves on news →Email me when RNAC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RNAC's baseline. Nothing else.
Recent RNAC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | -0.41% | +0.55% | |
| Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis | Press release | GlobeNewswire | -0.34% | -0.55% | |
| Form 8-K Cartesian Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | -0.55% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | -3.95% | -1.76% | |
| Cartesian Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.37% | -0.76% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | +0.17% | -0.34% | |
| Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +3.30% | |
| Form 10-Q Cartesian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.30% | |
| Form 8-K Cartesian Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.30% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | -2.86% | +2.62% | |
| Form 8-K Cartesian Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.10% | -4.65% | |
| Cartesian Therapeutics Announces New Employment Inducement Grant | Press release | GlobeNewswire | -3.46% | -11.25% | |
| Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases | Press release | GlobeNewswire | +21.68% | -2.28% | |
| Form 8-K Cartesian Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +21.68% | -2.28% | |
| Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 | Press release | GlobeNewswire | -3.01% | -6.11% | |
| Form 8-K Cartesian Therapeutics, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -3.01% | -6.11% | |
| Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Press release | GlobeNewswire | +1.79% | +4.07% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | +1.93% | +11.59% | |
| Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -2.96% | |
| Form 10-Q Cartesian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.96% | |
| Form 8-K Cartesian Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.96% | |
| Form S-8 Cartesian Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.96% | |
| Form DEF 14A Cartesian Therapeutics, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.55% | |
| Form DEFA14A Cartesian Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.55% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Cartesian Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | +2.50% | |
| Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +4.58% | +37.71% | |
| Form 10-K Cartesian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.58% | +37.71% | |
| Form 8-K Cartesian Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +4.58% | +37.71% | |
| Cartesian Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.29% | +1.75% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | +0.51% | +1.02% | |
| Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Press release | GlobeNewswire | +0.99% | +1.61% | |
| Form 8-K Cartesian Therapeutics, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | +1.61% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | -0.37% | +3.08% | |
| Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors | Press release | GlobeNewswire | +1.21% | -2.83% | |
| Form 8-K Cartesian Therapeutics, For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | -2.83% | |
| Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +17.98% | +26.25% | |
| Form 10-Q Cartesian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +17.98% | +26.25% | |
| Form 8-K Cartesian Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +17.98% | +26.25% | |
| Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors | Press release | GlobeNewswire | +1.23% | -0.61% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | +1.23% | -0.61% | |
| Form 8-K Cartesian Therapeutics, For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | -0.61% | |
| Form 8-K Cartesian Therapeutics, For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -5.69% | |
| Form 8-K Cartesian Therapeutics, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +4.28% | |
| Cartesian Therapeutics Announces New Employment Inducement Grant | Press release | GlobeNewswire | -0.86% | -2.40% | |
| Cartesian Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.89% | -3.83% | |
| Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -7.95% | |
| Form 10-Q Cartesian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -7.95% | |
| Form 8-K Cartesian Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.95% | |
| Cartesian Therapeutics Announces New Employment Inducement Grants | Press release | GlobeNewswire | -1.83% | -5.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RNAC section they belong to.
Where else RNAC is measured.
RNAC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cartesian Therapeutics, Inc.'s median reaction calculated?
Every labeled RNAC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 285 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of RNAC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RNAC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.